Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $8K (cash outflow) fell 50.0% year over year, ahead of the -80.5% change in trailing-twelve-month capital expenditures. Over 3 fiscal years it compounded at +128.9% a year.
Context
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -50.0% holds above the trailing-twelve-month pace of -80.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (24K) USD
- Year-over-year change
- +66.7%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (24K) | +66.7% |
| FY2024 | 2024-12-31 | (72K) | -500.0% |
| FY2023 | 2023-12-31 | (12K) | -500.0% |
| FY2022 | 2022-12-31 | (2K) | +93.1% |
| FY2021 | 2021-12-31 | (29K) | — |
Capital Expenditures vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -80.5% is the lowest of 9, against a peer median of -35.8%.
- Over three fiscal years its annual growth of +128.9% compares with a peer median of -20.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.63M USD | -19.2% | -8.3% | — |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$745.58K CAD | -52.4% | -14.0% | 4.1% |
| LTM Mar 2026 | $463K USD | -16.3% | -75.3% | 0.2% | |
CBUSCibus, Inc. | LTM Mar 2026 | $402K USD | -53.8% | -27.6% | 9.4% |
| LTM Mar 2026 | $116K USD | -58.6% | +12.9% | — | |
| LTM Mar 2026 | $25K USD | -61.5% | -84.6% | — | |
| LTM Mar 2026 | $16K USD | -80.5% | +128.9% | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | +100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | +100.0% | — | — | |
| Peer median (excluding UNCY) | — | -35.8% | -20.8% | 2.1% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Depreciation & Amortization | 13K | 161K | 284K | 428K | 572K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 966K | 1.05M | 1.77M | 2.35M | 2.64M |
| Change in Working Capital | (105K) | 1.18M | (93K) | (427K) | (5.95M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.24M | 1.27M | 1.28M | 790K | (2.51M) |
| Other Working Capital | (1.35M) | (89K) | (1.37M) | (1.22M) | (3.45M) |
| Other Non-Cash Items | 3.38M | 21K | 10.3M | 5.8M | (2.02M) |
| Operating Cash Flow | (5.77M) | (15.65M) | (18.28M) | (28.58M) | (31.32M) |
| Capital Expenditures | (29K) | (2K) | (12K) | (72K) | (24K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (12.07M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (29K) | (2K) | (12K) | (72K) | (12.1M) |
| Debt Repayment | (15K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 22.27M | 11K | 0 | 683K | 48.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | (1.1M) | 0 |
| Other Financing Activities | 119K | (482K) | (2.65M) | (4.5M) | (1.61M) |
| Financing Cash Flow | 22.38M | (471K) | 27.54M | 45.09M | 46.47M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.58M | (16.12M) | 9.25M | 16.44M | 3.06M |
| Free Cash Flow | (5.8M) | (15.65M) | (18.3M) | (28.65M) | (31.34M) |
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.